Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

124.43USD
28 Mar 2017
Change (% chg)

$-0.43 (-0.34%)
Prev Close
$124.86
Open
$124.61
Day's High
$125.45
Day's Low
$123.76
Volume
3,059,647
Avg. Vol
4,217,759
52-wk High
$127.64
52-wk Low
$94.42

Latest Key Developments (Source: Significant Developments)

Cipher Pharmaceuticals appoints Robert Tessarolo as CEO
Monday, 20 Mar 2017 04:00pm EDT 

Cipher Pharmaceuticals Inc : Cipher Pharmaceuticals appoints Robert Tessarolo as CEO . Says Tessarolo has been appointed president and chief executive officer of Cipher, effective April 17, 2017 .Cipher Pharmaceuticals Inc - Tessarolo most recently held position of vice president & general manager with Celgene Corporation.  Full Article

Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene
Monday, 13 Mar 2017 07:30am EDT 

Agios Pharmaceuticals Inc : Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene . Says Celgene will pay Agios an $8 million designation fee for MTAP pathway program . Agios Pharmaceuticals Inc - Celgene will have an opt-in right on program up through Phase 1 dose escalation for at least a $30 million fee . Agios Pharmaceuticals Inc - Agios will be eligible for up to $169 million in clinical and regulatory milestone payments .Agios Pharmaceuticals - co, Celgene to have global co-development and co-commercialization rights with worldwide 50/50 cost and profit share on MTAP pathway program.  Full Article

Juno Therapeutics reports qtrly net loss per share $0.51
Wednesday, 1 Mar 2017 04:05pm EST 

Juno Therapeutics Inc : Juno Therapeutics reports fourth quarter and 2016 financial results . Juno Therapeutics Inc - 2017 cash burn guidance of $270 million to $300 million . Juno Therapeutics Inc sees 2017 capital expenditures estimated to be between $22 million and $27 million . Juno Therapeutics Inc sees 2017 operating burn estimated to be between $245 million and $275 million . Juno Therapeutics Inc qtrly net loss per share $0.51 . Juno Therapeutics Inc qtrly revenue $21.2 million versus $ 4.2 million . Q4 earnings per share view $-0.61, revenue view $14.6 million -- Thomson Reuters I/B/E/S . Juno Therapeutics Inc qtrly net loss per share non-gaap $0.65 .Says "discontinuing development of jcar015 in r/r adult all to focus on defined cell product in this setting".  Full Article

FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT
Wednesday, 22 Feb 2017 04:02pm EST 

Celgene Corp : FDA expands indication for Revlimid® (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT) . Celgene Corp - FDA expanded existing indication for revlimid 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy .Celgene Corp- approval was based on two large studies comparing revlimid maintenance therapy versus no maintenance.  Full Article

Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis
Friday, 17 Feb 2017 07:30am EST 

Celgene Corp : Celgene announces positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis . Celgene Corp - safety and tolerability consistent with phase ii studies . Celgene Corp - study met its primary endpoint in reducing annualized relapse rate (arr) and measured secondary endpoints, compared to interferon (ifn) β-1a (avonex(reg)) . Says study met its primary endpoint .Celgene corp - confirmatory Phase III radiance trial data expected in q2 of 2017.  Full Article

Celgene receives second subpoena relating to past inquiry - SEC filing
Friday, 10 Feb 2017 06:04am EST 

Celgene Corp : Says received a second subpoena requesting materials primarily related to patient assistance to a past inquiry - sec filing . Celgene - subpoena recevied in nov 2016 requests materials related to patient assistance programs, including co's support of 501(c)(3) organizations .Celgene Corp says it is cooperating with the requests.  Full Article

Celgene CEO says tax reform could provide significant benefit to U.S. economy, healthcare industry - Conf Call
Thursday, 26 Jan 2017 09:59am EST 

Celgene Corp : Celgene says Q4 topline growth was predominantly volume driven with 14 percent of growth coming from product volume: Conf Call . Celgene says to continue its share repurchase program in 2017: Conf Call . Celgene says Abraxane growth in U.S. continues to be relatively stable in spite of significant competition in lung & breast cancer: Conf Call . Celgene says they have a strong chance of growing annually, each and every year throughout the decade beyond 2020: Conf Call . Celgene says keeping an open mind on capital allocation, including dividends : Conf Call . Celgene CEO is optimistic that Trump government is focusing on preserving, enhancing competitive marketplace as a way to balance value & economics of healthcare . Celgene CEO says they have to see how repeal & replacement of Obamacare plays out . Celgene CEO says in relation to Trump government: "We think it's going to be a pro-innovation, pro-industry policy environment" . Celgene CEO says overall Celgene is "guardedly optimistic" about expected corporate tax reform; cites growing optimism that it will be pro-innovation . Celgene CEO says tax reform could provide significant long-term benefits to U.S. economy, healthcare industry and "really level the playing field" Further company coverage: [CELG.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Celgene reports earnings per share $0.53
Thursday, 26 Jan 2017 07:30am EST 

Celgene Corp : Celgene reports fourth quarter and full-year 2016 operating and financial results . Q4 revenue $2.98 billion versus I/B/E/S view $3.02 billion . Q4 earnings per share $0.53 . Q4 earnings per share view $1.59 -- Thomson Reuters I/B/E/S . Celgene Corp - Revlimid sales for Q4 increased 16 percent to $1,808 million . Celgene Corp - Abraxane sales for Q4 were $266 million, a decrease of 1 percent, year-over-year . Celgene Corp - Sees 2017 total revenue approximately $13.0 billion to $13.4 billion . Celgene Corp - Sees 2017 Revlimid net sales approximately $8.0 billion to $8.3 billion . Celgene Corp - Sees 2017 adjusted operating margin approximately 56.5 percent . Celgene Corp - sees 2017 GAAP diluted EPS $5.85 to $6.21 . Celgene Corp - sees 2017 adjusted diluted EPS $7.10 to $7.25 . Celgene Corp sees 2017 GAAP operating margin approximately 45.5 percent .FY 2017 earnings per share view $7.15, revenue view $13.29 billion -- Thomson Reuters I/B/E/S.  Full Article

Medidata Solutions says Celgene increased adoption of Medidata Clinical Cloud
Thursday, 12 Jan 2017 08:30am EST 

Celgene Corp :Medidata Solutions - Celgene increases adoption of Medidata Clinical Cloud.  Full Article

Celgene updates 2017, long-term outlook
Monday, 9 Jan 2017 11:38am EST 

Celgene : CEO says 2016 sales $11.2 billion . Celgene sees 2017 adjusted EPS $7.10 to $7.75, revenue $13 billion to $13.4 billion . Celgene sees 2017 Revlimid sales $8 billion to $8.3 billion . Celgene sees 2020 sales greater than $21 billion . Celgene says expects to file seeking approval for Ozanimod in multiple sclerosis by year end . Celgene CEO says 4 of 14 products in development have multibillion-dollar potential . Celgene says 2020 forecast largely based on growing existing products .Celgene says "vast majority" of growth projections based on volume rather than price increases.  Full Article

More From Around the Web

BRIEF-Oncolytics Biotech enters collaboration with Myeloma UK and Celgene

* Oncolytics biotech enters into first-in-class collaboration with Myeloma UK and Celgene using Reolysin in combination with Imnovid or Revlimid in patients with Myeloma